AUS
NZ
UK
CA
USA
IND
ImmuPharma PLC (LSE:IMM) has reported progress in developing treatments for autoimmune diseases, with a focus on Systemic Lupus Erythematosus (SLE) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). In its recent update accompanying its interim results, the company highlighted key developments in its clinical programmes.
Unlike conventional treatments, the company's drug P140 targets the malfunctioning immune system without suppressing it. This unique mechanism opens up potential for broader applications beyond the two main conditions for which it is currently being tested.
For SLE, preparations are underway for a new phase III clinical trial, in collaboration with Simbec-Orion. This upcoming trial will utilize a higher monthly dose of P140 compared to the previous study, completed in 2018, with the aim of improving patient outcomes.
In the case of CIDP, a rare autoimmune disorder affecting the nervous system, ImmuPharma is planning a phase II/III study following positive feedback from US regulators. The company is close to submitting an Investigational New Drug (IND) application, with Simbec-Orion also managing this trial. CIDP remains a key area of focus as the company moves closer to clinical development.
Tim McCarthy, chairman and CEO of ImmuPharma, expressed confidence in the development of P140 for both SLE and CIDP. He emphasized the board's commitment to advancing these late-stage clinical assets while securing further partnerships for P140. McCarthy highlighted the scientific progress made in recent months, including refinements to the study protocols for SLE and CIDP, and new insights into P140's mechanism of action, which has reinforced optimism about the success of these upcoming trials.
In addition to advancements with P140, ImmuPharma’s preclinical programmes focused on antifungal and antibacterial treatments are also progressing as planned.
On the financial front, the company has significantly reduced its losses, cutting them in half to £0.4 million for the six months ending June 30. ImmuPharma held a cash balance of £1.1 million at the end of the period, providing financial stability as it moves forward with its clinical programmes.
In June, ImmuPharma raised £1.5 million from the sale of shares in its sister company, Incanthera. Additionally, the company announced the extension of 7.3 million warrants in Incanthera until March 31 of next year, providing further financial flexibility for the future.
